Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Is a deal/buyout in 2022 realistic?

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Nov 20, 2022 1:05pm

210 Views

Post# 35113860

RE:RE:Is a deal/buyout in 2022 realistic?

Thanks to all for valuable comments.

KSW, the final AWARE 1 poster is available on the ONCY web site. I had thought it would address BC issues like PFS or OS, but that trial is about the tumor microenvironment so to speak. Hence its results address those kinds of issues.

If you take a look at that poster, could you interpret anything about the biomarker information and how that is demonstrated or tested for submission to regulators?

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”